Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Exclusion Criteria

• •1. Histologically or cytologically confirmed mixed SCLC and NSCLC.
• •2. Symptomatic, untreated or active central nervous system metastases.
• •3. Systemic therapy with immunosuppressive agents within 2 weeks prior to initiation of study treatment
• •4. With any active autoimmune disease or history of autoimmune disease.
• •5. Inadequately controlled hypertension.
• •6. Tumor infiltration into the great vessels on imaging.
• •7. History of hemoptysis ≥2.5ml per episode within 1 month prior to initiation of study treatment.
• •8. Uncontrolled tumor-related pain.
• •9. Patients with active hepatitis B or hepatitis C
• •10. Severe infections within 4 weeks prior to initiation of study treatment.
• •11. Active tuberculosis within one year prior to initiation of study treatment.